174 related articles for article (PubMed ID: 15078100)
1. Kinetic mechanism of quinone oxidoreductase 2 and its inhibition by the antimalarial quinolines.
Kwiek JJ; Haystead TA; Rudolph J
Biochemistry; 2004 Apr; 43(15):4538-47. PubMed ID: 15078100
[TBL] [Abstract][Full Text] [Related]
2. Insights into the redox cycle of human quinone reductase 2.
Reybier K; Perio P; Ferry G; Bouajila J; Delagrange P; Boutin JA; Nepveu F
Free Radic Res; 2011 Oct; 45(10):1184-95. PubMed ID: 21762045
[TBL] [Abstract][Full Text] [Related]
3. Old and new inhibitors of quinone reductase 2.
Ferry G; Hecht S; Berger S; Moulharat N; Coge F; Guillaumet G; Leclerc V; Yous S; Delagrange P; Boutin JA
Chem Biol Interact; 2010 Jul; 186(2):103-9. PubMed ID: 20399199
[TBL] [Abstract][Full Text] [Related]
4. Characterization of the melatoninergic MT3 binding site on the NRH:quinone oxidoreductase 2 enzyme.
Mailliet F; Ferry G; Vella F; Berger S; Cogé F; Chomarat P; Mallet C; Guénin SP; Guillaumet G; Viaud-Massuard MC; Yous S; Delagrange P; Boutin JA
Biochem Pharmacol; 2005 Dec; 71(1-2):74-88. PubMed ID: 16293234
[TBL] [Abstract][Full Text] [Related]
5. Relationship of stopped flow to steady state parameters in the dimeric copper amine oxidase from Hansenula polymorpha and the role of zinc in inhibiting activity at alternate copper-containing subunits.
Takahashi K; Klinman JP
Biochemistry; 2006 Apr; 45(14):4683-94. PubMed ID: 16584203
[TBL] [Abstract][Full Text] [Related]
6. Quinone reductase 2 substrate specificity and inhibition pharmacology.
Boutin JA; Chatelain-Egger F; Vella F; Delagrange P; Ferry G
Chem Biol Interact; 2005 Feb; 151(3):213-28. PubMed ID: 15733542
[TBL] [Abstract][Full Text] [Related]
7. NRH:quinone reductase 2: an enzyme of surprises and mysteries.
Vella F; Ferry G; Delagrange P; Boutin JA
Biochem Pharmacol; 2005 Dec; 71(1-2):1-12. PubMed ID: 16253210
[TBL] [Abstract][Full Text] [Related]
8. MT3/QR2 melatonin binding site does not use melatonin as a substrate or a co-substrate.
Boutin JA; Marcheteau E; Hennig P; Moulharat N; Berger S; Delagrange P; Bouchet JP; Ferry G
J Pineal Res; 2008 Nov; 45(4):524-31. PubMed ID: 18826489
[TBL] [Abstract][Full Text] [Related]
9. Potentiometric and further kinetic characterization of the flavin-binding domain of Saccharomyces cerevisiae flavocytochrome b2. Inhibition by anions binding in the active site.
Cénas N; Lê KH; Terrier M; Lederer F
Biochemistry; 2007 Apr; 46(15):4661-70. PubMed ID: 17373777
[TBL] [Abstract][Full Text] [Related]
10. Crystal structure of human quinone reductase type 2, a metalloflavoprotein.
Foster CE; Bianchet MA; Talalay P; Zhao Q; Amzel LM
Biochemistry; 1999 Aug; 38(31):9881-6. PubMed ID: 10433694
[TBL] [Abstract][Full Text] [Related]
11. Crystal structure of a new type of NADPH-dependent quinone oxidoreductase (QOR2) from Escherichia coli.
Kim IK; Yim HS; Kim MK; Kim DW; Kim YM; Cha SS; Kang SO
J Mol Biol; 2008 May; 379(2):372-84. PubMed ID: 18455185
[TBL] [Abstract][Full Text] [Related]
12. Binding and reactivity of Candida albicans estrogen binding protein with steroid and other substrates.
Buckman J; Miller SM
Biochemistry; 1998 Oct; 37(40):14326-36. PubMed ID: 9760270
[TBL] [Abstract][Full Text] [Related]
13. Crystal structure of quinone reductase 2 in complex with resveratrol.
Buryanovskyy L; Fu Y; Boyd M; Ma Y; Hsieh TC; Wu JM; Zhang Z
Biochemistry; 2004 Sep; 43(36):11417-26. PubMed ID: 15350128
[TBL] [Abstract][Full Text] [Related]
14. Cellular knock-down of quinone reductase 2: a laborious road to successful inhibition by RNA interference.
Chomarat P; Cogé F; Guénin SP; Mailliet F; Vella F; Mallet C; Giraudet S; Nagel N; Leonce S; Ferry G; Delagrange P; Boutin JA
Biochimie; 2007 Oct; 89(10):1264-75. PubMed ID: 17714848
[TBL] [Abstract][Full Text] [Related]
15. Kinetic analysis of the L-ornithine transcarbamoylase from Pseudomonas savastanoi pv. phaseolicola that is resistant to the transition state analogue (R)-N delta-(N'-sulfodiaminophosphinyl)-L-ornithine.
Templeton MD; Reinhardt LA; Collyer CA; Mitchell RE; Cleland WW
Biochemistry; 2005 Mar; 44(11):4408-15. PubMed ID: 15766270
[TBL] [Abstract][Full Text] [Related]
16. Crystal structure of quinone reductase 2 in complex with cancer prodrug CB1954.
Fu Y; Buryanovskyy L; Zhang Z
Biochem Biophys Res Commun; 2005 Oct; 336(1):332-8. PubMed ID: 16129418
[TBL] [Abstract][Full Text] [Related]
17. Radical phosphate transfer mechanism for the thiamin diphosphate- and FAD-dependent pyruvate oxidase from Lactobacillus plantarum. Kinetic coupling of intercofactor electron transfer with phosphate transfer to acetyl-thiamin diphosphate via a transient FAD semiquinone/hydroxyethyl-ThDP radical pair.
Tittmann K; Wille G; Golbik R; Weidner A; Ghisla S; Hübner G
Biochemistry; 2005 Oct; 44(40):13291-303. PubMed ID: 16201755
[TBL] [Abstract][Full Text] [Related]
18. The antimalarial drugs chloroquine and primaquine inhibit pyridoxal kinase, an essential enzyme for vitamin B6 production.
Kimura T; Shirakawa R; Yaoita N; Hayashi T; Nagano K; Horiuchi H
FEBS Lett; 2014 Oct; 588(20):3673-6. PubMed ID: 25157434
[TBL] [Abstract][Full Text] [Related]
19. Kinetic, thermodynamic and X-ray structural insights into the interaction of melatonin and analogues with quinone reductase 2.
Calamini B; Santarsiero BD; Boutin JA; Mesecar AD
Biochem J; 2008 Jul; 413(1):81-91. PubMed ID: 18254726
[TBL] [Abstract][Full Text] [Related]
20. Discovery of novel targets of quinoline drugs in the human purine binding proteome.
Graves PR; Kwiek JJ; Fadden P; Ray R; Hardeman K; Coley AM; Foley M; Haystead TA
Mol Pharmacol; 2002 Dec; 62(6):1364-72. PubMed ID: 12435804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
